Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...

An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.